Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2014-11-12 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Placement Cleansing Notice 1 page 67.2KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release titled 'On-Sale Cleansing Notice – Issue of Placement Shares' dated 13 November 2014. It details the issuance of 210 million fully paid ordinary shares by Imugene Limited as part of a placement to institutional and sophisticated investors. The notice references compliance with sections of the Corporations Act related to issuing shares without disclosure and provides details about the securities issued. The content focuses on a capital raising event and the legal notice related to the share issuance, not a full financial report or earnings release. The document length is short (1887 characters) and is clearly an announcement of a capital/financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-11-12 English
Appendix 3B 12 pages 305.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new ordinary fully paid shares, including the number of securities issued, issue price, purpose of the issue, security holder approvals, and quotation agreements with the ASX (Australian Securities Exchange). The content focuses on the announcement and procedural details related to a capital raising event and the listing of new securities. There are no financial statements, earnings data, or management discussion of financial results. The document is regulatory in nature, specifically related to capital issuance and quotation on the stock exchange. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2014-11-11 English
Additional placement details 2 pages 60.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Imugene Limited regarding the completion of a share placement, detailing the number of shares issued, the price, dilution percentages, and fees related to the placement. It references Listing Rules and shareholder approval but does not contain financial statements or detailed financial analysis. The document is short (2482 characters) and focuses on capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing.
2014-11-11 English
Share Purchase Plan Offer Document & Cleansing Notice 8 pages 659.5KB
Capital/Financing Update Classification · 95% confidence The document is a detailed letter and accompanying materials from Imugene Limited offering shareholders the opportunity to participate in a Share Purchase Plan (SPP). It includes information about the offer price, application process, eligibility, risks, terms and conditions, and intended use of funds. The document discusses a recent placement of shares and the opportunity for existing shareholders to purchase additional shares at a discount. This is a clear announcement related to a capital raising activity and changes in the company's capital structure through a share issue. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to capital changes. The document is not a proxy statement, AGM material, or management report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2014-11-06 English
Investor Presentation 28 pages 3.8MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's technology, leadership, scientific advisory board, product pipeline, and market positioning. It includes forward-looking statements, disclaimers, and detailed descriptions of the company's immuno-oncology focus and HER-2 targeting therapies. There are no financial statements, regulatory certifications, or voting results. The content is consistent with a presentation aimed at investors to inform them about the company's strategy, products, and market opportunity. Therefore, this document fits the category of an Investor Presentation (IP).
2014-11-04 English
Share Purchase Plan Cleansing Notice 1 page 63.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release titled 'Cleansing Notice – Share purchase plan' dated 5 November 2014. It references ASIC Class Order 09/425 and the Corporations Act 2001, indicating compliance with regulatory requirements for issuing shares under a share purchase plan (SPP) without disclosure. The document is short (1347 characters) and serves as a formal notice to the ASX about the upcoming share offer and compliance status. It does not contain financial statements, detailed financial data, or management discussion. It is an announcement related to capital raising activities but not a full capital/financing update report. Given the nature of the document as a regulatory notice about share issuance under a plan, the most appropriate classification is Share Issue/Capital Change (SHA).
2014-11-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.